Nice | Rivaroxaban in Acute Coronary Syndrome (ACS)

27th May 2015 by Louise Hudman

Nice | Rivaroxaban in Acute Coronary Syndrome (ACS)

This new guideline from Nice states that rivaroxaban can now be used after ACS with elevated cardiac enzymes. It should be used either with aspirin, or with aspirin and clopidogrel together.

  • It decreases the combined end points of MI, CVA or deaths from cardiovascular events by 20%.
  • There is a 3 x increased risk of major bleeding, so bleeding risk must be assessed.
  • Use beyond 12m hasn’t been studied, so use beyond that point is for clinical judgement.

It is generally started about a week after the event, so it is likely that we will be starting it, though hopefully it will be advised in the discharge summary.

Read for free

Sign up to access everything.

Free trial

Login

Already a member? Login to view this content.

Login

"The NASGP and the GP locum chambers that I'm in have provided invaluable assistance both before and through Covid-19 to me as a full-time GP locum. All aspects of locum work have been made easier as a result of membership and the chamber's support structure - from accessing work, to ensuring invoicing and documentation is all sorted, and access to other locums as peer support. Having a chamber manager means I feel more secure and can devote more of my energy on my clinical work."

Dr Richard Smith

Dr Richard Smith

See the full list of features within our NASGP membership plans

Membership